Shopping Cart
Remove All
Your shopping cart is currently empty
BMS309403 is a potent and selective inhibitor of adipocyte fatty acid binding protein aFABP. It improves endothelial function in apolipoprotein E-deficient mice and cultured human endothelial cells. It interacts with the fatty acid binding pocket inside the protein and competitively inhibits the binding of endogenous fatty acids.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $30 | In Stock | In Stock | |
| 5 mg | $48 | In Stock | In Stock | |
| 10 mg | $85 | In Stock | In Stock | |
| 25 mg | $166 | In Stock | In Stock | |
| 50 mg | $216 | In Stock | In Stock | |
| 100 mg | $280 | In Stock | - | |
| 1 mL x 10 mM (in DMSO) | $53 | In Stock | In Stock |
| Description | BMS309403 is a potent and selective inhibitor of adipocyte fatty acid binding protein aFABP. It improves endothelial function in apolipoprotein E-deficient mice and cultured human endothelial cells. It interacts with the fatty acid binding pocket inside the protein and competitively inhibits the binding of endogenous fatty acids. |
| Targets&IC50 | FABP3: 250 nM , FABP4:< 2 nM, FABP5: 350 nM |
| In vitro | Treatment with BMS309403 significantly reduced MCP-1 production in THP-1 macrophages in a dose- and time-dependent manner.[1] |
| In vivo | METHODS: 3 weeks after the onset of diabetes, mice were orally treated with BMS309403 (40 mg/kg, daily) for 3 weeks. During treatment, monitor blood sugar levels. RESULTS BMS309403 can significantly reduce the protein expression of FABP4 in mouse retinal tissue and partially reduce blood glucose levels in mice. [2] |
| Molecular Weight | 474.55 |
| Formula | C31H26N2O3 |
| Cas No. | 300657-03-8 |
| Smiles | CCc1c(c(nn1-c1ccccc1-c1cccc(OCC(O)=O)c1)-c1ccccc1)-c1ccccc1 |
| Relative Density. | 1.17 g/cm3 |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||||||||||||
| Solubility Information | Ethanol: 20 mM, Heating is recommended. DMSO: 50 mg/mL (105.36 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.21 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
DMSO
| |||||||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.